These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 30093077

  • 1. [Key-studies on dupilumab].
    Velter C.
    Ann Dermatol Venereol; 2018; 145(8-9):532-538. PubMed ID: 30093077
    [No Abstract] [Full Text] [Related]

  • 2. [Current and upcoming treatments of adult atopic dermatitis].
    Lacour JP.
    Ann Dermatol Venereol; 2017 Dec; 144 Suppl 5():VS29-VS37. PubMed ID: 29433635
    [Abstract] [Full Text] [Related]

  • 3. [Not Available].
    Lacour JP.
    Ann Dermatol Venereol; 2019 Dec; 146(12S3):12S76-12S84. PubMed ID: 31997736
    [Abstract] [Full Text] [Related]

  • 4. Dupilumab for treatment of atopic dermatitis.
    Seegräber M, Srour J, Walter A, Knop M, Wollenberg A.
    Expert Rev Clin Pharmacol; 2018 May; 11(5):467-474. PubMed ID: 29557246
    [Abstract] [Full Text] [Related]

  • 5. Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus.
    Tavakolpour S.
    Dermatol Ther; 2016 Sep; 29(5):299. PubMed ID: 26800435
    [No Abstract] [Full Text] [Related]

  • 6. Dupilumab (Dupixent) for moderate to severe atopic dermatitis.
    Med Lett Drugs Ther; 2017 Apr 24; 59(1519):64-66. PubMed ID: 28419072
    [No Abstract] [Full Text] [Related]

  • 7. Monoclonal antibodies for the treatment of atopic dermatitis.
    Renert-Yuval Y, Guttman-Yassky E.
    Curr Opin Allergy Clin Immunol; 2018 Aug 24; 18(4):356-364. PubMed ID: 29870461
    [Abstract] [Full Text] [Related]

  • 8. A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis.
    Chipalkatti N, Lee N, Zancanaro P, Dumont N, Kachuk C, Rosmarin D.
    J Am Acad Dermatol; 2019 Apr 24; 80(4):1166-1167. PubMed ID: 30630024
    [No Abstract] [Full Text] [Related]

  • 9. Recall dermatitis at patch test sites in an atopic dermatitis patient treated with dupilumab.
    Collantes-Rodríguez C, Jiménez-Gallo D, Ossorio-García L, Villegas-Romero I, Linares-Barrios M.
    Contact Dermatitis; 2019 Jan 24; 80(1):69-70. PubMed ID: 30334260
    [No Abstract] [Full Text] [Related]

  • 10. The beginning of biological treatment era in the atopic dermatitis management.
    D'erme AM.
    Dermatol Ther; 2016 May 24; 29(3):208-9. PubMed ID: 26331894
    [No Abstract] [Full Text] [Related]

  • 11. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR.
    N Engl J Med; 2014 Jul 10; 371(2):130-9. PubMed ID: 25006719
    [Abstract] [Full Text] [Related]

  • 12. EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.
    Bakker DS, Ariens LFM, Giovannone B, Hijnen D, Delemarre EM, Knol E, Nierkens S, de Bruin-Weller MS, Thijs JL, Drylewicz J.
    Allergy; 2020 Dec 10; 75(12):3287-3289. PubMed ID: 33305359
    [No Abstract] [Full Text] [Related]

  • 13. Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody.
    Scheinfeld N.
    Dermatol Online J; 2005 Mar 01; 11(1):2. PubMed ID: 15748543
    [Abstract] [Full Text] [Related]

  • 14. Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.
    Blakely K, Gooderham M, Papp K.
    Skin Therapy Lett; 2016 Mar 01; 21(2):1-5. PubMed ID: 27223113
    [Abstract] [Full Text] [Related]

  • 15. Dupilumab for off-label treatment of moderate to severe childhood atopic dermatitis.
    Jorge E, Clark J.
    Cutis; 2018 Sep 01; 102(3):201-204. PubMed ID: 30372706
    [Abstract] [Full Text] [Related]

  • 16. Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment.
    Eichenfield LF, Stein Gold LF.
    Semin Cutan Med Surg; 2017 Mar 01; 36(2 Suppl 2):S45-S48. PubMed ID: 28654711
    [Abstract] [Full Text] [Related]

  • 17. Atopic dermatitis: real-life experience with tralokinumab after dupilumab failure: a case series.
    Amoedo P, Rosa G, Baudrier T, Pedrosa AF, Cruz MJ.
    An Bras Dermatol; 2024 Mar 01; 99(5):721-724. PubMed ID: 38834396
    [No Abstract] [Full Text] [Related]

  • 18. Drug evaluation review: dupilumab in atopic dermatitis.
    Hamilton JD, Ungar B, Guttman-Yassky E.
    Immunotherapy; 2015 Mar 01; 7(10):1043-58. PubMed ID: 26598956
    [Abstract] [Full Text] [Related]

  • 19. Alopecia Universalis and Atopic Dermatitis Improvement with Dupilumab: Demonstration of a Shared Pathophysiology and Clinical Efficacy.
    Dobkin H, Mullen R, Zirwas M.
    Skinmed; 2019 Mar 01; 17(2):139-140. PubMed ID: 31145072
    [No Abstract] [Full Text] [Related]

  • 20. Dupixent® (Dupilumab): A Newly Approved Interleukin-4 Receptor Antagonist for the Treatment of Atopic Dermatitis in Pediatric Patients.
    Gupta AK, Love RP, Abramovits W, Vincent KD.
    Skinmed; 2019 Mar 01; 17(2):107-109. PubMed ID: 31145061
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.